# 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma

> **NCT06537596** · PHASE1 · RECRUITING · sponsor: **Telix Pharmaceuticals (Innovations) Pty Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

## Key facts

- **NCT ID:** NCT06537596
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-31
- **Primary completion:** 2026-03
- **Final completion:** 2026-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06537596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06537596, "89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06537596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*